VivoSeq
Other

Safety Issues

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Safety Issues is an early-stage landscape with 4 programs across 3 companies. The most active players are Taiwan Bio Therapeutics Inc., Nanjing Immunophage Biotech Co., Ltd, Etern Therapeutics Wuxi Limited.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

T

Taiwan Bio Therapeutics Inc.

1 program

Phase 1N

Nanjing Immunophage Biotech Co., Ltd

1 program

PreclinicalE

Etern Therapeutics Wuxi Limited

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed1 · 33%
Terminated1 · 33%
Enrolling by invitation1 · 33%

Clinical Trials

Trial Activity

A Phase 1/2a, Multi-center, Non-randomized, Open-label, Dose-escalation, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of IPG7236 Administered Orally as a Single Agent in Patients With Advanced Solid Tumors
Completed·NNanjing Immunophage Biotech Co., Ltd·Preclinical·NCT05142592·34 enrolled
Intracoronary Administration of OmniMSC-AMI for Acute ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention-Phase I Clinical Trial to Assess the Safety.
Terminated·TTaiwan Bio Therapeutics Inc.·Phase 1·NCT05724576·1 enrolled
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ETD-001 Gel in Healthy Chinese Subjects
Enrolling by invitation·EEtern Therapeutics Wuxi Limited·Phase 1·NCT07674862·56 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)